Estonian
Albanian
Arabic
Armenian
Azerbaijani
Belarusian
Bengali
Bosnian
Catalan
Czech
Danish
Deutsch
Dutch
English
Estonian
Finnish
Français
Greek
Haitian Creole
Hebrew
Hindi
Hungarian
Icelandic
Indonesian
Irish
Italian
Japanese
Korean
Latvian
Lithuanian
Macedonian
Mongolian
Norwegian
Persian
Polish
Portuguese
Romanian
Russian
Serbian
Slovak
Slovenian
Spanish
Swahili
Swedish
Turkish
Ukrainian
Vietnamese
Български
中文(简体)
中文(繁體)
9 tulemused
Testing the Addition of Nivolumab to Chemotherapy in Treatment of Soft Tissue Sarcoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVES:
I. To determine the progression free survival (PFS) for paclitaxel with and without nivolumab in subjects with taxane naive angiosarcoma.
II. To determine the overall response rate (ORR) of nivolumab in combination with cabozantinib S-malate (cabozantinib) in patients with taxane
Cabozantinib With Radiation Therapy for the Treatment of Sarcomas of the Extremities
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OUTLINE: This is a phase I, dose-escalation study of cabozantinib followed by a phase II, dose-expansion study.
Patients receive cabozantinib S-malate orally (PO) once daily (QD) on days 1-21. Cycles repeat every 21 days until the completion of radiation therapy in the absence of disease progression
Cabozantinib-S-Malate in Treating Younger Patients With Recurrent, Refractory, or Newly Diagnosed Sarcomas, Wilms Tumor, or Other Rare Tumors
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVES:
I. To determine the objective response rate (complete response + partial response) of cabozantinib-s-malate (XL184) in children and young adults.
II. To estimate whether XL184 therapy either improves the disease control rate at 4 months in patients with recurrent measurable
Cabozantinib S-malate in Treating Patients With Relapsed Osteosarcoma or Ewing Sarcoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVES:
I. To evaluate the antitumor activity of cabozantinib s-malate (cabozantinib) for Ewing sarcomas, in terms of 6-month objectives response as per the Response Evaluation Criteria in Solid Tumors, Revised (RECIST version [v]1.1).
II. To evaluate the antitumor activity of
Cabozantinib-S-Malate in Treating Patients With Refractory Thyroid Cancer
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVES:
I. The objective response rate, defined as the proportion of patients who have had a partial response (PR) or complete response (CR) within the first 6 months after initiation of therapy with cabozantinib (cabozantinib-s-malate).
SECONDARY OBJECTIVES:
I. To assess duration of
Sunitinib or Cediranib for Alveolar Soft Part Sarcoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
Background:
- Alveolar soft part sarcoma (ASPS) is a rare, highly vascular tumor accounting for less than 1% of soft tissue sarcomas. There is no effective systemic treatment for patients with metastatic ASPS. Little is known with regards to relevant molecular markers as potential therapeutic
Sunitinib Malate in Treating East African Patients With Kaposi Sarcoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
PRIMARY OBJECTIVES:
I. Determine the clinical response of sunitinib malate in patients with Kaposi sarcoma (KS) in Uganda and Kenya.
II. Compare clinical response rates in endemic versus epidemic (AIDS) KS. III. Determine the safety and tolerability of sunitinib malate in patients with endemic or
Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
OBJECTIVES:
Primary
- Determine the response rate (complete response and partial response) in patients with metastatic, locally advanced, or locally recurrent non-gastrointestinal stromal tumor sarcomas treated with sunitinib malate.
Secondary
- Determine the 16- and 24-week progression-free
Phase II Study of Sunitinib Malate for Metastatic and/or Surgically Unresectable Soft Tissue Sarcoma
Ainult registreeritud kasutajad saavad artikleid tõlkida
Logi sisse
This is an open label single site Phase II clinical trial to identify a potentially promising therapy dose for Sunitinib malate, an oral multi-kinase inhibitor. The study drug will be taken orally once daily on days 1 through 28 of each 42 day cycle. Treatment will be continued until there is either
Kõige täiuslikum ravimtaimede andmebaas, mida toetab teadus
- Töötab 55 keeles
- Taimsed ravimid, mida toetab teadus
- Maitsetaimede äratundmine pildi järgi
- Interaktiivne GPS-kaart - märgistage ürdid asukohas (varsti)
- Lugege oma otsinguga seotud teaduspublikatsioone
- Otsige ravimtaimi nende mõju järgi
- Korraldage oma huvisid ja hoidke end kursis uudisteuuringute, kliiniliste uuringute ja patentidega
Sisestage sümptom või haigus ja lugege ravimtaimede kohta, mis võivad aidata, tippige ürdi ja vaadake haigusi ja sümptomeid, mille vastu seda kasutatakse.
* Kogu teave põhineb avaldatud teaduslikel uuringutel
